Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations
- 18 July 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (3), 519-524
- https://doi.org/10.1093/cid/ciy576
Abstract
Ceftazidime/avibactam and meropenem/vaborbactam are changing the management of invasive infections due to carbapenem-resistant Enterobacteriaceae (CRE), leading to higher rates of clinical cure, decreased mortality, and decreased rates of acute kidney injury compared with colistin-based regimens. However, these 2 agents are not interchangeable with regard to management of CRE infections, and clinicians need to be aware of their differences. This review focuses on differences in the in vitro activity of these agents as a function of mechanism of carbapenem resistance, the clinical data supporting their superiority over colistin-based therapy, and the differences between agents with regard to propensity for selection of resistance. Furthermore, considerations and recommendations for hospital formularies and antibiotic stewardship programs regarding positioning of these agents are discussed.Keywords
Funding Information
- Allergan
- Melinta
- Merck
- Shionogi
- Zavante
- Achaogen
This publication has 32 references indexed in Scilit:
- In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 CarbapenemaseAntimicrobial Agents and Chemotherapy, 2015
- Ceftazidime-Avibactam Activity Tested against Enterobacteriaceae Isolates from U.S. Hospitals (2011 to 2013) and Characterization of β-Lactamase-Producing StrainsAntimicrobial Agents and Chemotherapy, 2015
- Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsOpen Forum Infectious Diseases, 2015
- Prevalence and molecular characterisation of New Delhi metallo-β-lactamases NDM-1, NDM-5, NDM-6 and NDM-7 in multidrug-resistant Enterobacteriaceae from IndiaInternational Journal of Antimicrobial Agents, 2014
- In Vitro Activities of Ceftazidime-Avibactam and Aztreonam-Avibactam against 372 Gram-Negative Bacilli Collected in 2011 and 2012 from 11 Teaching Hospitals in ChinaAntimicrobial Agents and Chemotherapy, 2014
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesThe Lancet Infectious Diseases, 2013
- Activity of biapenem (RPX2003) combined with the boronate -lactamase inhibitor RPX7009 against carbapenem-resistant EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2013
- OXA-48-like carbapenemases: the phantom menaceJournal of Antimicrobial Chemotherapy, 2012
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2011
- Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain ofKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2001